References
- Hayner G. N., Mc Kinney H. MDMA: the dark side of ecstasy. J Psychoactive Drugs 1986; 18: 341–347
- Brown C., Osterloh J. Multiple severe complications from recreational ingestion of MDMA (Ecstasy). JAMA 1987; 258: 780–781
- Screaton G. R., Singer M., Cairns H. S., Thrasher A., Sarner M., Cohen S. L. Hyperpyrexia and rhabdo‐myolysis after MDMA (‘ecstasy’) abuse. Lancet 1992; 339: 677–678
- Fahal J. H., Sallomi D. F., Yaqoob M., Bell G. M. Acute renal failure after ecstasy. BMJ 1992; 305: 29
- Singarajah C., Lavies N. G. An overdose of ecstasy. A role for dantrolene. Anaesthesia 1992; 47: 686–687
- Chadwick I. S., Curry P. D., Linsley A., Freemont A. J., Doran B. 3,4‐methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 1991; 84: 371
- Campkin N. T. A., Davies U. M. Another death from Ecstasy. J R Soc Med 1992; 85: 61
- Henry J. A., Jeffreys K. J., Dawling S. Toxicity and deaths from 3,4‐methylenedioxymethamphetamine (“ecstasy”). Lancet 1992; 340: 384–387
- Forrest A. R. W., Galloway J. H., Marsh I. D., Strachan G. A., Clark J. C. A fatal overdose with 3,4‐methylenedioxy‐amphetamine derivatives. Forensic Sci Int 1994; 64: 57–59
- Dowling G. P., McDonough E. T., Bost R. O. “Eve” and “Ecstasy”. A report of five deaths associated with the use of MDEA and MDMA. JAMA 1987; 257: 1615–1617
- Tehan B., Hardern R., Bodenham A. Hyperthermia associated with 3,4‐methylenedioxyethamphetamine (‘Eve’). Anaesthesia 1993; 48: 507–510
- Callaway C. W., Geyer M. A. Tolerance and cross‐tolerance to the activating effects of 3,4‐methylenedioxymethamphetamine and a 5‐hydroxytryptaminelB agonist. J Pharmacol Exp Ther 1992; 263: 318–326
- Schmidt C. J., Black C. K., Abbate G. M., Taylor V. L. Methylenedioxymethamphetamine‐induced hyperthermia and neurotoxicity are independently mediated by 5‐HT2 receptors. Brain Res 1990; 529: 85–90
- Gordon C. J., Watkinson W. P., O'Callaghan J. P., Miller D. B. Effects of 3,4 methylenedioxymefhamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 1991; 38: 339–344
- Boja J. W., Schechter M. D. Possible serotonergic and dopaminergic mediation of the N‐ethyl‐3,4‐methylene‐dioxyamphetamine discriminative stimulus. Eur J Pharmacol 1991; 202: 347–353
- Johnson M. P., Hoffman A. J., Nichols D. E. Effects of the enantiomers of MDA, MDMA and related analogues on ‘3H’ serotonin and ‘3H’ dopamine release from supervised rat brain slices. Eur J Pharmacol 1986; 132: 269–276
- Schmidt C. J. Acute administration of methylene‐dioxymethamphetamine: comparison with the neurochemical effects of its N‐desmethyl and N‐ethyl analogs. Eur J Pharmacol 1987; 136: 81–88
- Verebey K., Alrazi J., Jaffe J. H. The complications of ‘ecstasy’ (MDMA). JAMA 1988; 259: 1649–1650
- McGuire P., Fahy T. Chronic paranoid psychosis after misuse of MDMA (‘ecstasy’). BMJ 1991; 302: 697
- Whitaker‐Azmitia P. M., Aronson T. A. “Ecstasy” (MDMA)‐induced panic. Am J Psychiatry 1989; 146: 119
- Hermle L., Spitzer M., Borchardt D., Kovar K. A., Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?. Neuropsychopharmacology 1993; 8: 171–176
- Ricaurte G., Bryan G., Strauss L., Seiden L., Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986–988